Once-per-cycle pegfilgrastim (Neulasta) for the management of chemotherapy-induced neutropenia

Seminars in Oncology

Volumn 30, Issue 4 SUPPL. 13, 2003, Pages 24-30

  Crawford, Jeffrey ^a,b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b DUKE CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; COLONY STIMULATING FACTOR; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; ETOPOSIDE; MACROGOL; METHYLPREDNISOLONE; PREDNISONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; VINCRISTINE;

BONE MARROW SUPPRESSION; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COVALENT BOND; DOUBLE BLIND PROCEDURE; DRUG HALF LIFE; FEBRILE NEUTROPENIA; HUMAN; LYMPHOMA; NEUTROPENIA; NEUTROPHIL; NONHODGKIN LYMPHOMA; PATIENT COMPLIANCE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REVIEW;

EID: 0141856611     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0093-7754(03)00314-2     Document Type: Article

References (21)

1. Blackwell S, Crawford J: Filgrastim (r-metHuG-CSF) in the chemotherapy setting, in Morstyn G, Dexter TM, Foote M (eds): Filgrastim (r-metHuG-CSF) in Clinical Practice. New York, NY, Marcel Dekker, 1994, 103-106
2. Crawford J, Ozer H, Stoller R, et al: Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med 325:164-170, 1991
3. Pettengell R, Gurney H, Radford JA, et al: Granulocyte colony-stimulating factor to prevent dose-limiting neutropenia in non-Hodgkin's lymphoma: A randomized controlled trial. Blood 80:1430-1436, 1992
4. Trillet-Lenoir V, Green J, Manegold C, et al: Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy. Eur J Cancer 29A:319-324, 1993
5. Molineux G, Kinstler O, Briddell B, et al: A new form of filgrastim with sustained duration in vivo and enhanced ability to mobilize PBPC in both mice and humans. Exp Hematol 27:1724-1734, 1999
6. Molineux G: Pegylation: Engineering improved pharmaceuticals for enhanced therapy. Cancer Treat Rev 28:13-16, 2002 (suppl A)
7. Yowell SL, Blackwell S: Novel effects with polyethylene glycol modified pharmaceuticals. Cancer Treat Rev 28:3-6, 2002 (suppl A)
8. Delgado C, Francis GE, Fisher D: The uses and properties of PEG-linked proteins. Crit Rev Ther Drug Carrier Syst 9:249-304, 1992
9. Crawford J: Clinical benefits of pegylated proteins in oncology. Cancer Treat Rev 28:1-2, 2002 (suppl A)
10. Crawford J: Clinical uses of pegylated pharmaceuticals in oncology. Cancer Treat Rev 28:7-11, 2002 (suppl A)
11. Lord BI, Woolford LB, Molineux G: Kinetics of neutrophil production in normal and neutropenic animals during the response to filgrastim (r-metHu-G-CSF) or filgrastim SD/01 (PEG-r-metHu G-CSF). Clin Cancer Res 7:2085-2090, 2001
12. Johnston E, Crawford J, Blackwell S, et al: Randomized, dose-escalation study of SD/01 compared with daily filgrastim in patients receiving chemotherapy. J Clin Oncol 18:2522-2528, 2000
13. Holmes FA, Jones SE, O'Shaughnessy J, et al: Comparable efficacy and safety profiles of once-per-cycle pegfilgrastim and daily injection filgrastim in chemotherapy-induced neutropenia: A multicenter dose-finding study in women with breast cancer. Ann Oncol 13:903-909, 2002
14. Holmes FA, O'Shaughnessy JA, Vukelja S, et al: Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer. J Clin Oncol 20:727-731, 2002
15. Yang BB, Lum P, Renwick J, et al: Pharmacokinetic rationale for a fixed-dose regimen of a sustained-duration form of filgrastim in cancer patients. Blood 96:157b, 2000 (abstr 4384)
16. Green MD, Koelbl H, Baselga J, et al: A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. Ann Oncol 14:29-35, 2003
17. Shogan J, Koelbl H, Holmes FA: Pegfilgrastim shows safety and efficacy similar to filgrastim in elderly patients with breast cancer. Proc Am Soc Clin Oncol 21:66a, 2002 (abstr 260)
18. Siena S, Piccart MJ, Holmes FA, et al: A combined analysis of two pivotal randomized trials of a single dose of pegfilgrastim per chemotherapy cycle and daily filgrastim in patients with stage II-IV breast cancer. Oncol Rep 10:715-724, 2003
19. Hiddemann W, Grigg A, Solal-Celigny P, et al: An open-label, randomized parallel, dose-ranging study of single administration SD/01 vs daily filgrastim as an adjunct to chemotherapy in elderly patients with non-Hodgkin's lymphoma. Haematol J 1:184, 2001 (abstr 685)
20. Vose JM, Crump M, Lazarus H, et al: Randomized, multicenter, open-label study of pegfilgrastim compared with daily filgrastim after chemotherapy for lymphoma. J Clin Oncol 21:514-519, 2003
21. George S, Yunus F, Yang BB, et al: Pharmacokinetic profiles of fixed dose single pegfilgrastim administration in patients with non-Hodgkin's lymphoma. Blood 98:27b, 2001 (abstr 3700)